According to , Marchmont Innovation News portal, scientists at the Institute of Biology in the northwestern Russian region of Komi and their colleagues in Tomsk, in Siberia, have developed a pharmacological substance that is likely to become the basis of a new drug candidate to treat blood circulation disorders.
Their product is reported to show antioxidative, hemorrheological, antithrombogenic, neuroprotective and retina-protective activities, thus improving the properties of blood and increasing cerebral blood flow for effective treatment of patients with chronic blood circulation disorders.
Three-year preclinical trials conducted in partnership with the Institute of Pharmacology and Regenerative Medicine in Tomsk have led the team to believe that there is no analog in the global pharmaceutical market to match the combination of the new drug candidate’s useful properties. Clinical trial phase testing is expected to take between five and seven years.